NHWK NightHawk Biosciences, Inc.

NightHawk Biosciences Inc is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system. By leveraging its proprietary platforms, the company is advancing its first-in-class product portfolio with a focus on cancer and inflammatory and infectious diseases. Its current pipeline has two categories: Oncology and Biodefense.

$2.52  -0.13 (-4.91%)
As of 06/28/2022 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  05/03/2022
Outstanding shares:  25,649,824
Average volume:  74,180
Market cap:   $63,098,567
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   103.62
PB ratio:   1.44
PS ratio:   0.46
Return on equity:   1.39%
Net income %:   0.48%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy